UB Paderborn / Katalog / Suche / in CDI

Sex‐based differences in outcomes with bivalirudin or unfractionated heparin for transcatheter aortic valve replacement: Results from the BRAVO‐3 randomized trial

Catheterization and cardiovascular interventions, 2017-01, Vol.89 (1), p.144-153

2017

Volltextzugriff (PDF)

European workshop in periodontal health and cardiovascular disease consensus document

European heart journal supplements, 2010-04, Vol.12 (suppl-B), p.B13-B22

2010

Volltextzugriff (PDF)

Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial

European heart journal, 2014-09, Vol.35 (36), p.2460-2467

2014

Volltextzugriff (PDF)

Bivalirudin use in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Insights from the prospective, multi-centre EUROVISION registry

Acute cardiac care, 2014-12, Vol.16 (4), p.127

2014

Volltextzugriff (PDF)

Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction

The American heart journal, 2001-03, Vol.141 (3), p.435-438

2001

Volltextzugriff (PDF)

Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges

International journal of cardiology, 2013-09, Vol.167 (5), p.1772-1782

2013

Volltextzugriff (PDF)

P1935Pharmacokinetic and pharmacodynamic assessment of a lipid-based aspirin formulation: results of a prospective, randomised, crossover study

European heart journal, 2019-10, Vol.40 (Supplement_1)

2019

Volltextzugriff (PDF)

Anti-platelet factor 4/heparin antibodies: An independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes

Circulation (New York, N.Y.), 2003-05, Vol.107 (18), p.2307-2312

2003

Volltextzugriff (PDF)

PCV58 - Health Economic Impact of Angiographic Risk Features in Pci Patients

Value in health, 2016-05, Vol.19 (3), p.A49-A49

2016

Volltextzugriff (PDF)

Health Economic Impact of Angiographic Risk Features in Pci Patients

Value in health, 2016-05, Vol.19 (3), p.A49-A49

2016

Volltextzugriff (PDF)

Cardiotoxicity of Cancer Therapy

Cancer investigation, 1999, Vol.17 (6), p.408-422

1999

Volltextzugriff (PDF)

Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial

European heart journal, 2018-12, Vol.39 (46), p.4112-4121

2018

Volltextzugriff (PDF)

Efficient removal of apixaban with extracorporeal hemoadsorption

European heart journal. Acute cardiovascular care, 2021-04, Vol.10 (Supplement_1)

2021

Volltextzugriff (PDF)

THE EFFICACY AND SAFETY OF CANGRELOR FOR PATIENTS UNDERGOING SINGLE VESSEL VERSUS MULTI VESSEL PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CHAMPION PHOENIX TRIAL

Journal of the American College of Cardiology, 2018-03, Vol.71 (11), p.A29-A29

2018

Volltextzugriff (PDF)

History repeats itself

Circulation (New York, N.Y.), 2001-02, Vol.103 (8), p.E48-E48

2001

Volltextzugriff (PDF)

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)

Circulation (New York, N.Y.), 2016-09, Vol.134 (10), p.723-733

2016

Volltextzugriff (PDF)

Preoperative factors predisposing to early postoperative atrial fibrillation after isolated coronary artery bypass grafting

The American journal of cardiology, 2000-03, Vol.85 (6), p.763-764

2000

Volltextzugriff (PDF)

P2852 Superior clinical outcomes with abciximab versus eptifibatide: a contemporary, single centre, single operator, non-randomized comparison of 500 consecutive percutaneous coronary interventions

European heart journal, 2003-03, Vol.24 (5), p.543

DELIARGYRIS, E

2003

Volltextzugriff (PDF)

Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance

Thrombosis and haemostasis, 2002-11, Vol.88 (5), p.711

2002

Volltextzugriff (PDF)

Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial

Circulation (New York, N.Y.), 2016-01, Vol.133 (3), p.248-255

2016

Volltextzugriff (PDF)

The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX

European heart journal, 2016-04, Vol.37 (14), p.1122-1130

2016

Volltextzugriff (PDF)

Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy

European heart journal, 2013-06, Vol.34 (22), p.1621-1629

2013

Volltextzugriff (PDF)

Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)

Circulation. Cardiovascular interventions, 2018-04, Vol.11 (4), p.e005635-e005635

2018

Volltextzugriff (PDF)

Relation of serum levels of mast cell tryptase of left ventricular systolic function, left ventricular volume or congestive heart failure

Journal of cardiac failure, 2004-02, Vol.10 (1), p.31-35

2004

Volltextzugriff (PDF)

Cangrelor compared with clopidogrel in patients with prior myocardial infarction – Insights from the CHAMPION trials

International journal of cardiology, 2018-01, Vol.250, p.49-55

2018

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Sex‐based differences in outcomes with bivalirudin or unfractionated heparin for transcatheter aortic valve replacement: Results from the BRAVO‐3 randomized trial

European workshop in periodontal health and cardiovascular disease consensus document

Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial

Bivalirudin use in patients undergoing percutaneous coronary intervention for acute myocardial infarction. Insights from the prospective, multi-centre EUROVISION registry

Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction

Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges

P1935Pharmacokinetic and pharmacodynamic assessment of a lipid-based aspirin formulation: results of a prospective, randomised, crossover study

Anti-platelet factor 4/heparin antibodies: An independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes

PCV58 - Health Economic Impact of Angiographic Risk Features in Pci Patients

Health Economic Impact of Angiographic Risk Features in Pci Patients

Cardiotoxicity of Cancer Therapy

Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial

Efficient removal of apixaban with extracorporeal hemoadsorption

THE EFFICACY AND SAFETY OF CANGRELOR FOR PATIENTS UNDERGOING SINGLE VESSEL VERSUS MULTI VESSEL PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CHAMPION PHOENIX TRIAL

History repeats itself

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)

Preoperative factors predisposing to early postoperative atrial fibrillation after isolated coronary artery bypass grafting

P2852 Superior clinical outcomes with abciximab versus eptifibatide: a contemporary, single centre, single operator, non-randomized comparison of 500 consecutive percutaneous coronary interventions

Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance

Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial

The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX

Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy

Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)

Relation of serum levels of mast cell tryptase of left ventricular systolic function, left ventricular volume or congestive heart failure

Cangrelor compared with clopidogrel in patients with prior myocardial infarction – Insights from the CHAMPION trials

Suchergebnisse filtern